Evidence map›Paper›PMID 37724858›Full record

ArticleJournal of clinical microbiology2023

Plasmid-mediated drug resistance in mycobacteria: the tip of the iceberg?

Keith M Derbyshire, Max Salfinger

Open access · greenAbstract readComment
In one paragraph

Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Keith M DerbyshireDivision of Genetics, Wadsworth Center, New York State Department of Health , Albany, New York, USA.ORCID 0000-0003-3404-8312
Max SalfingerCollege of Public Health, University of South Florida , Tampa, Florida, USA.ORCID 0000-0003-4061-6486
New York State Department of Health · USUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrolides, such as clarithromycin, are crucial in the treatment of nontuberculous mycobacteria (NTM). NTM are notoriously innately drug resistant, which has made the dependence on macrolides for their treatment even more important. Not surprisingly, resistance to macrolides has been documented in some NTM, including

Indexed as

MycobacteriumMycobacterium chelonaeMycobacterium Infections, NontuberculousAnti-Bacterial AgentsChromosomesClarithromycinDrug Resistance, BacterialHumansMacrolidesMethyltransferasesNontuberculous MycobacteriaAnti-Bacterial AgentsClarithromycinMacrolidesMethyltransferasesrRNA (adenosine-O-2'-)methyltransferasedrug resistanceerm(55)horizontal gene transfermycobacteriamycobacterium chelonaenontuberculous mycobacteriaplasmid

Identifiers

PMID37724858
PMCPMC10595058
OpenAlexW4386844786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.